10-KPeriod: FY2005

DEXCOM INC Annual Report, Year Ended Dec 31, 2005

Filed February 27, 2006For Securities:DXCM

Summary

This 10-K filing from DexCom, Inc. (DXCM) on February 27, 2006, details the company's progress in developing continuous glucose monitoring (CGM) systems. As a development-stage company, DexCom has not yet generated revenue but has invested heavily in research and development for both a short-term (3-day) and a long-term (up to 1-year) CGM system. The company has submitted a Premarket Approval (PMA) application for its short-term system to the FDA and is awaiting a decision. The report highlights the significant market opportunity in diabetes management and the limitations of existing finger-stick glucose monitoring methods, positioning DexCom's technology as a potential solution offering greater convenience and real-time data. The company faces substantial risks, including the uncertainty of FDA approval, intense competition from established medical device manufacturers, potential intellectual property disputes (including a lawsuit filed by Abbott Diabetes Care), and the need for significant future funding. DexCom's financial performance reflects its development stage, with substantial net losses incurred to date. The company's strategy focuses on establishing its technology as a leader in CGM, rapidly bringing products to market, maintaining high quality standards, and building a direct sales and marketing effort. The filing also provides detailed information on clinical trials, manufacturing capabilities, intellectual property, and regulatory challenges.

Key Highlights

  • 1DexCom is a development-stage company focused on continuous glucose monitoring (CGM) systems for diabetes management, with no current revenue.
  • 2The company has submitted a Premarket Approval (PMA) application to the FDA for its short-term CGM system and is awaiting a decision.
  • 3DexCom is developing both a short-term (3-day) and a long-term (up to 1-year) CGM system, aiming to overcome limitations of current finger-stick methods.
  • 4The company faces significant risks including regulatory approval uncertainty, intense competition, and ongoing patent litigation with Abbott Diabetes Care.
  • 5Substantial R&D investments have been made, resulting in significant net losses as of December 31, 2005.
  • 6DexCom has raised capital through private placements and an Initial Public Offering (IPO) in April 2005, providing approximately $50.5 million in net proceeds.
  • 7The company is building a direct sales and marketing infrastructure in anticipation of potential product launch.

Frequently Asked Questions

DexCom is a development-stage medical device company focused on the design and development of continuous glucose monitoring (CGM) systems for people with diabetes. They have not yet generated revenue from product sales.

DexCom submitted a Premarket Approval (PMA) application for its STS in March 2005, received expedited review status, and is currently awaiting a decision from the FDA. They have responded to a request for additional information from the FDA.

The company faces significant risks including the uncertainty of obtaining FDA approval for its products, intense competition from established medical device manufacturers, potential intellectual property disputes (including a patent infringement lawsuit filed by Abbott Diabetes Care), the need for substantial future funding, and the risk that its products may not achieve market acceptance even if approved.

DexCom has financed its operations primarily through private placements and an Initial Public Offering (IPO) in April 2005, which provided approximately $50.5 million in net proceeds. As of December 31, 2005, the company had incurred significant net losses since its inception and had a deficit accumulated during the development stage of $83.8 million.